Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.40
Bid: 110.40
Ask: 111.20
Change: 0.40 (0.36%)
Spread: 0.80 (0.725%)
Open: 110.00
High: 111.20
Low: 110.00
Prev. Close: 110.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: DMGT Rises, Euromoney Falls On Share Return

Mon, 04th Mar 2019 10:41

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday:----------FTSE 100 - WINNERS----------Rightmove, up 4.2%. Shares in the company were rebounding from losses on Friday amid concerns the property portal's agency numbers dropped last year. The stock closed down 2.1% on Friday.----------FTSE 100 - LOSERS----------Rolls-Royce Group Holdings, down 2.5%. The jet engine maker reined in efforts to join a fighter jet programme being developed by Turkey, the Financial Times reported on Sunday. Rolls-Royce had been working with Turkish industrial company Kale Group to bid for the contract to develop the TF-X jet. The jet would have been the first locally made jet in Turkey. However, talks between Rolls-Royce and Turkey were said to have run into issues last year over matters relating to intellectual property sharing and the involvement of a Qatari-Turkish firm. After failing to find a compromise, Rolls-Royce was reported to have "all but abandoned" its efforts to win the contract.----------British American Tobacco, down 0.5%. The Quebec Court of Appeal after the market close on Friday dismissed an appeal by three tobacco companies against a CAD15.60 billion judgement against them in class action lawsuits that have been running for some 20 years. The three companies facing the class action are the wholly-owned subsidiaries of BAT, Philip Morris International, and Japan Tobacco in Canada, being Imperial Tobacco Canada, Rothmans, Benson & Hedges, and JTI MacDonald, respectively.----------FTSE 250 - WINNERS----------Energean Oil & Gas, up 4.8%. The oil and gas company said it has started its 2019 drilling programme in Israel. Energean's programme consists of drilling three development wells at the offshore Karish North prospect. Energean intends to batch drill the top-hole sections of the wells, to allow for operational efficiency and cost savings. Energean has another six drilling options available in its contract with drilling services firm Stena Drilling, following the four-well campaign.----------Syncona, up 3.5%. The life sciences investor said investee company Nightsar Therapeutics has agreed to be acquired by US neuroscience healthcare firm Biogen for USD877 million, giving a 72% internal rate of return to Syncona. Syncona currently holds a 38% stake in Nightstar, and as a result the offer will generate GBP254.6 million in proceeds. Syncona said it will put the proceeds towards building and funding portfolio companies. The acquisition, is expected to be completed in the second quarter of 2019.----------Ted Baker, up 2.6%. The fashion retailer said Chief Executive Officer Ray Kelvin resigned with immediate effect following allegations of misconduct that were made against him. Kelvin took a voluntary leave of absence from his role as CEO of Ted Baker in December last year, after he was accused by the company's staff of forced "hugging" and inappropriate touching and comments. Kelvin has denied all allegations of misconduct. Since then, Ted Baker commissioned the law firm Herbert Smith Freehills to investigate the allegations. It is expected the lawyers will conclude their investigation at the end of the first quarter or early in the second quarter of 2019. Ted Baker said acting Chief Executive Officer Lindsay Page has agreed to continue in this role.----------Senior, up 1.1%. The aerospace and defence engineer hiked its final dividend after profit expanded amid wider margins and higher revenue, with the order book also reported as "strong". In 2018, pretax profit rose 17% to GBP61.3 million from GBP52.2 million the year prior, as revenue rose 5.9% to GBP1.08 billion from GBP1.02 billion the year before. Excluding one-off charges, including those related to acquisitions, pension charges and lawsuits, adjusted pretax profit climbed 14% to GBP83.0 million from GBP73.1 million. Senior proposed a 5.23 pence per share final dividend, up 6.7% from 4.90p the year prior. For the full year the dividend was increased 6.8% to 7.42p from 6.95p the year before. ----------FTSE 250 - LOSERS----------Rotork, down 4.5%. The valve actuators maker cautioned of a slowdown in revenue in 2019 despite posting strong 2018 results. For recent year, Rotork reported pretax profit rose 50% to GBP120.7 million from GBP80.6 million in 2017 and revenue increased 8.3% to GBP695.7 million from GBP642.2 million. Rotork hiked its 2018 dividend by 9.3% to 5.90 pence from 5.40p the prior year. However, Rotork said after "double digit [organic constant currency] growth" in 2018, it was "mindful" of macroeconomic uncertainty, and as such was anticipating slower 2019 revenue growth and modest sales.----------OTHER MAIN MARKET AND AIM - WINNERS----------Daily Mail & General Trust, up 5.0%. The Daily Mail newspaper publisher said the shareholding of the family of Lord Rothermere will increase to 36% from 24% as a result of a planned return of Euromoney Institutional Investor shares to DMGT shareholders and a related DMGT share reduction. The rise in stake is because the Rothmere family will not take part in the Euromoney share return, and will only participate partially in the DMGT share reduction and associated GBP200 million cash return. DMGT said each of its A share holder will receive 0.19933 Euromoney share, plus 68.13p in cash. The company said the number of its A shares will be reduced as part of the capital distributions, on the basis of a reduction of 0.46409 of a share for each existing A share. Euromoney shares were down 4.6% despite its CEO saying the company will benefit from a wider shareholder base.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 40%. The film finance and services provider said its two largest units had experienced weaker performances in the second half. As such, the company now expects annual profit to fall as much as half on the year prior. In total, the problems at its Completion Contracts and Insurance Agency units are expected to dent earnings before interest and tax by around USD6 million. For the year ending March, FFI now anticipates underlying Ebit between USD7.5 million and USD11.5 million. This is down between 55% to 31% from the USD16.6 million reported the year prior. For the year ended March 2018, FFI reported pretax profit of USD5.3 million on revenue of USD58.9 million.----------

More News
13 Jun 2024 16:05

UK earnings, trading statements calendar - next 7 days

Friday 14 June 
Tesco PLCTrading Statement
Monday 17 June 
Monks Investment Trust PLCFull Year Results
Tuesday 18 June 
Ashtead Group PLCFull Year Results
Global Smaller Cos Trust PLCFull Year Results
Intercede Group PLCFull Year Results
Oxford BioDynamics PLCHalf Year Results
Tatton Asset Management PLCFull Year Results
Telecom Plus PLCFull Year Results
Wednesday 19 June 
Berkeley Group HoldingsFull Year Results
NextEnergy Solar Fund LtdFull Year Results
Schroder European Real Estate Investment Trust PLCHalf Year Results
Speedy Hire PLCFull Year Results
Severfield PLCFull Year Results
Young & Co's Brewery PLCFull Year Results
Thursday 20 June 
Alpha Financial Markets Consulting PLCFull Year Results
Atrato Onsite Energy PLCHalf Year Results
CMC Markets PLCFull Year Results
Cordiant Digital Infrastructure LtdFull Year Results
DS Smith PLCFull Year Results
Syncona LtdFull Year Results
Urban Logistics REIT PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

Read more
9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.

Read more
9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.